 Ceftazidime amikacin versus ceftazidime vancomycin empiric therapy febrile neutropenic children cancer antibiotic regimens ceftazidime amikacin ceftazidime vancomycin prospective randomized clinical trial empiric therapy febrile granulocytopenic children cancer rate response similar groups prevalence secondary gram-negative bacteremia group vancomycin Adverse reactions latter group Mortality groups Adjustment independent predictors response treatment means multivariate analysis lack remarkable difference responses regimens use vancomycin amikacin combination ceftazidime outcome treatment fever infection granulocytopenic children cancer use vancomycin increased frequency secondary infections due gram-negative bacteria adverse reactions